WEBULL
WebtradeDownload

Roivant Sciences (ROIV) Wins FDA Approval For LISRAYA, Is The Upside Already Priced In?

Simply Wall St · 2d ago

Roivant Sciences (NasdaqGS:ROIV) just crossed a major milestone with US FDA approval of LISRAYA, or brepocitinib, for adults with dermatomyositis, and the company has moved straight into commercial launch.

Roivant Sciences’ share price has moved sharply over the past year, with a 90 day share price return of 20.4% and year to date share price return of 56.9%, while the 1 year total shareholder return of 173.75% suggests that momentum has been building ahead of and around this FDA approval.

Spot opportunities beyond Roivant Sciences by scanning a curated set of biopharma stocks that combine clinical catalysts with solid fundamentals through our 21 high quality undiscovered gems.

After a surge like Roivant Sciences has just seen around the LISRAYA approval, some investors think the move is done, while others see it as the start of a new phase. So is it better to buy now or wait for a cooler entry once the valuation work is clear?

Most Popular Narrative: 244.1% Overvalued

Roivant Sciences last closed at $34.41, while the most followed narrative on the stock assigns a fair value of $10. This gap frames a much more cautious story than the recent share price strength might suggest.

The "Roivant Compounding Fantasy" relies on a lazy sum-of-the-parts calculation, treating binary litigation windfalls and a crowded autoimmune pipeline as a bulletproof thesis. Here is why the market is mispricing the structural friction inside Roivant's hub-and-spoke model: 1. The IP Litigation Trap: Relying on the Pfizer/BioNTech mRNA lawsuit for near-term re-rating is highly speculative. Modern’s settlement was a tactical win, but a full-scale global docket against Pfizer can drag out for years with brutal appellate friction. Courts historically discount retroactive royalty damages far more than retail bulls realize.

Read the complete narrative.

Curious why this narrative sees such a gap to the current Roivant Sciences share price. Revenue growth, margins and future profit assumptions all play a crucial role in the $10 fair value story. The real drivers sit inside those forecasts.

According to AnimalDoctorKwon, the narrative leans heavily on how Roivant Sciences redeploys past deal proceeds, the competitive intensity in autoimmune markets and the reliance on litigation and asset flips. It anchors on a discount rate of 7.57% to bring those long dated cash flow expectations back to today, which sharply pulls the fair value below the current market price.

Result: Fair Value of $10 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, there are still clear risks to that cautious Roivant Sciences thesis if the autoimmune portfolio performs well or the IP litigation delivers faster clarity than expected.

Find out about the key risks to this Roivant Sciences narrative.

Next Steps

With sentiment around Roivant Sciences running hot after LISRAYA, it helps to move quickly and pressure test the story yourself. Start by weighing Roivant Sciences’ upside potential against the 3 key rewards.

Looking for more investment ideas beyond Roivant Sciences?

If Roivant Sciences has your attention after LISRAYA, do not stop there. Use the Simply Wall Street Screener to spot other opportunities before the crowd.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.